Cipla Limited has informed the Exchange regarding Outcome of Board Meeting held on May 13, 2025.
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty 100 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Cipla's board approved audited consolidated and standalone results for Q4 and FY ended March 31, 2025, along with an unqualified audit opinion from Walker Chandiok & Co LLP. Consolidated revenue from operations rose about 6.9% YoY to ₹27,547.62 Cr, while consolidated net profit jumped roughly 26.8% to ₹5,269.20 Cr (FY24 base was pulled down by a ₹194.82 Cr Pulmazole exceptional charge). Standalone revenue grew nearly 15% to ₹19,044.85 Cr with net profit up around 26.5% at ₹5,157.65 Cr. The board recommended a final dividend of ₹13 per share plus a one-time special dividend of ₹3 per share to mark Cipla's 90th year, taking the total payout to ₹16 per share with a record date of June 27, 2025. Operating cash flow remained strong at about ₹5,005 Cr, and the company continues to carry a long-standing NPPA/DPCO contingent liability of roughly ₹2,011 Cr which is under litigation and not provided for.
Solid double-digit profit growth and the additional special dividend signal strong cash generation and shareholder-friendly capital allocation, which should be viewed positively by investors. The unresolved NPPA demand remains a watch item but is not a near-term cash concern since no provision has been made.